- cafead   May 09, 2024 at 07:22: PM
via Acumen Pharmaceuticals has dosed the first patient in ALTITUDE-AD, a Phase II trial designed to evaluate the clinical efficacy and safety of its lead drug sabirnetug (ACU193) in patients with early Alzheimer’s disease.
article source
article source